Solid vs. Liquid Biopsy in Somatic Oncology
Key Takeaways
Summary
- •Tissue Remains the Diagnostic Gold Standard: Tissue biopsy is still required for histology, immunohistochemistry (e.g., PD-L1), and initial somatic genomic profiling in solid tumors.
- •Liquid Biopsy Captures What a Single Sample Can’t: ctDNA/cfDNA and CTC profiling offers minimally invasive, repeatable sampling that reflects spatial and temporal tumor heterogeneity better than a single tissue biopsy.
- •Concordance Shifts Across the Disease Course: Tissue-liquid NGS concordance for guideline-recommended biomarkers reaches 94.8–100% at diagnosis but drops sharply at progression, as clonal evolution diverges the two compartments.
- •Tumor-Informed ctDNA Leads on MRD Sensitivity: Tumor-informed assays achieve higher sensitivity and specificity for minimal residual disease detection than tumor-agnostic assays, at the cost of requiring prior tumor tissue and longer assay design time.
- •Complementary, Not Competing: Current best practice under NCCN and ESMO frameworks favors complementary or sequential use of tissue and liquid biopsy, not substitution of one for the other.
Introduction
Somatic mutation profiling now sits at the center of precision oncology, guiding everything from first-line targeted therapy selection to relapse monitoring after curative-intent surgery. Two sampling strategies dominate clinical and research workflows: solid (tissue) biopsy, which remains the histopathological and molecular reference standard, and liquid biopsy, which profiles circulating tumor material, primarily circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), from blood or other body fluids.
For researchers designing translational studies, students building a foundation in molecular oncology, and clinicians interpreting next-generation sequencing (NGS) reports, the practical question is rarely “which is better” in the abstract. It is: which sample type answers the clinical or research question in front of you, at what sensitivity, and with what turnaround time and cost. This article lays out the technical basis for that decision.
1. What Each Modality Actually Measures
1.1 Solid (tissue) biopsy
Tissue biopsy (via core needle, excisional, or endoscopic sampling) provides a physical specimen for histopathology, immunohistochemistry, and nucleic acid extraction for NGS. It is the only method that preserves tumor architecture, grade, and spatial context, and it remains required to establish a definitive cancer diagnosis and histological subtype at presentation, providing essential information on tumor morphology, grade, and architecture, and enabling immunohistochemistry such as PD-L1 and tumor genomic profiling.
1.2 Liquid biopsy
Liquid biopsy analyzes tumor-derived material shed into biofluids, most commonly plasma. The main analytes are:
- ctDNA (circulating tumor DNA): fragments of tumor-derived cell-free DNA (cfDNA), released primarily via apoptosis and necrosis of tumor cells.
- CTCs (circulating tumor cells): intact tumor cells shed from the primary tumor into the bloodstream, distinct from the cfDNA fragments that constitute ctDNA.
- Emerging analytes: exosomal nucleic acids, cell-free RNA, and methylation signatures used in multi-cancer early detection assays.
Sample sources are not limited to blood: liquid biopsy also encompasses urine, saliva, and cerebrospinal fluid, the last of which requires a lumbar puncture, a materially more invasive collection than a venous draw.
2. Analytical and Clinical Performance
2.1 Concordance with tissue at initial diagnosis
Across NSCLC cohorts, liquid biopsy NGS for guideline-recommended biomarkers shows concordance with tissue NGS ranging from 94.8% to 100%, with liquid biopsy also reporting higher overall testing success and turnaround times averaging 26.8 days faster than tissue-based testing. In a retrospective analysis across two cancer centers, physicians based front-line treatment decisions on liquid biopsy results in 73.5% of cases versus 25.9% for tissue biopsy, largely on turnaround-time and sample-sufficiency grounds.
2.2 Concordance drops sharply at disease progression
Concordance is not stable across the disease course. In lung adenocarcinoma, tissue–liquid NGS concordance was 79.4% at initial diagnosis in treatment-naïve patients, falling to 40.0% at disease progression following first-line therapy. This decline reflects genuine biological divergence (clonal evolution under treatment pressure) rather than simple assay noise, and it is a critical point for interpreting discordant results in the clinic rather than assuming one platform is "wrong."
2.3 Tumor heterogeneity: liquid biopsy's structural advantage
A single tissue sample captures one spatial and temporal point in a tumor's evolution. Because different metastatic lesions can arise from divergent genetic subclones, a single tissue biopsy cannot adequately represent overall tumor heterogeneity. Formal systematic review work confirms that intratumoral heterogeneity and tumor purity introduce genuine sampling bias in mutation testing across solid cancers, with no formal guidelines existing to standardize how this bias is assessed or reported. In a prospective cohort of patients with acquired resistance to targeted therapy, plasma ctDNA identified clinically relevant resistance alterations that were absent from the matched tumor biopsy in 78% of cases: a direct demonstration that pooled circulating DNA can sample multiple tumor sites more comprehensively than one needle pass.
2.4 Where tissue retains the advantage
Tissue is not simply "worse but easier." It remains the higher-accuracy reference for detecting alterations from low-shedding tumors, and false negatives in liquid biopsy are a recognized failure mode, occurring in low-shedding tumors or in anatomically sequestered sites such as the peritoneum or central nervous system, where the blood–brain barrier limits ctDNA release into plasma. Liquid biopsy interpretation is also complicated by clonal hematopoiesis of indeterminate potential (CHIP), a source of false positives arising from age-related somatic mutations in blood cells that are unrelated to the tumor and can affect results independent of the technical assay's performance.
3. Clinical Decision Points Across the Patient Journey
| Clinical scenario | Preferred modality | Rationale |
|---|---|---|
| Initial diagnosis / histological subtyping | Tissue | Only tissue preserves architecture and enables IHC (e.g., PD-L1) |
| First-line biomarker testing, standard workflow | Tissue (guideline default) | NCCN Guidelines prefer tissue biopsies over liquid biopsies for initial biomarker testing and treatment decisions in metastatic solid tumors |
| Insufficient or unavailable tissue | Liquid | NCCN includes an explicit statement supporting liquid biopsy NGS when tissue is unavailable |
| Suspected resistance mechanism at progression | Liquid, informed by tissue where feasible | Captures subclonal resistance alterations tissue may miss, per concordance data above |
| Endocrine-resistance monitoring in HR+ metastatic breast cancer | Liquid | ESMO and other guidelines support liquid biopsy for detecting ESR1 mutations, which commonly arise after aromatase inhibitor therapy and drive endocrine resistance |
| Postoperative MRD detection / recurrence risk stratification | Liquid (tumor-informed preferred where feasible) | Enables serial, non-invasive monitoring impossible with repeat tissue sampling |
| Longitudinal treatment-response monitoring | Liquid | Repeatable; avoids cumulative procedural risk of serial biopsies |
4. Turnaround Time and Health-Economic Considerations
Turnaround time (TAT) differences are consistent and clinically meaningful across tumor types. General ranges place liquid biopsy TAT at seven to ten business days versus two to four weeks for tissue NGS. In breast cancer specifically, liquid biopsy results were available in 10–13 days compared with up to 33 days for tissue NGS. In a two-center NSCLC study, median TAT was 9.6 days for liquid NGS versus 36.4 days for tissue NGS (P < .0001), a finding the authors note is consistent with the NILE trial's comparison of 9 days for liquid biopsy against a substantially longer tissue TAT. For patients with aggressive, rapidly progressing disease, this gap can directly determine whether targeted therapy starts before or after a clinically significant window closes.
5. Practical Recommendations for Study and Workflow Design
Conclusion
Solid and liquid biopsy are not competing technologies converging towards a single winner: they are complementary tools answering different questions with different trade-offs in sensitivity, specificity, invasiveness and turnaround time. Tissue remains indispensable for diagnosis and histological characterisation; liquid biopsy is increasingly indispensable for capturing tumour heterogeneity, enabling serial monitoring and detecting resistance mechanisms without repeat invasive procedures. The current direction across ESMO, NCCN and the broader research literature is not substitution but integration: using each modality where its analytical strengths align with the clinical or research question at hand.
References
- Boukouris et al. Liquid biopsy in cancer diagnosis and prognosis: a paradigm shift in precision oncology. Frontiers in Molecular Biosciences, 2025.
- A Review of Liquid, Tissue-Based and Combined Next-Generation Sequencing. NCODA, 2026.
- Raez L, et al. Liquid Biopsy Versus Tissue Biopsy to Determine Front Line Therapy in Metastatic Non-Small Cell Lung Cancer (NSCLC). PubMed. / ScienceDirect
- Liquid biopsy in cancer: current status, challenges and future prospects. Signal Transduction and Targeted Therapy, Nature, 2024.
- When to Use Liquid Biopsy vs Tissue Biopsy in Cancer Care. Avitia, 2026.
- Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. PMC.
- A Tale of Two Biopsies: Liquid Biopsy vs Tissue Biopsy. BioChain Institute, 2025.
- Circulating Tumor DNA: A Pan-Cancer Biomarker in Solid Tumors. Annual Review of Medicine.
- Minimal residual disease in colorectal cancer. Tumor-informed versus tumor-agnostic approaches: unraveling the optimal strategy. Annals of Oncology, 2025.
- Predictive Effectiveness of Circulating Tumor DNA in Recurrent Early-Stage Non–Small Cell Lung Cancer: An Updated Meta-Analysis. JCO Precision Oncology.
- Clinical performance of tumor-informed versus tumor-agnostic ctDNA assays for colorectal cancer recurrence: A systematic review and diagnostic accuracy meta-analysis. Cancer Treatment Reviews, 2025.
- Tumor-Informed vs Tumor-Agnostic ctDNA: A Deep Dive Into MRD Assay Selection. Targeted Oncology.
- Santonja A, et al. Comparison of tumor-informed and tumor-naïve sequencing assays for ctDNA detection in breast cancer. EMBO Molecular Medicine, 2023.
- Heo S, et al. Analytical validation of a hybrid-approach combining tumor-informed and tumor-agnostic bespoke ctDNA panel assay for the sensitive detection of minimal residual disease. PLOS ONE, 2025.
- Brief Report: Discordance Between Liquid and Tissue Biopsy-Based Next-Generation Sequencing in Lung Adenocarcinoma at Disease Progression. Clinical Lung Cancer, 2023.
- Impact of tumor heterogeneity and tissue sampling for genetic mutation testing: a systematic review and post hoc analysis. ScienceDirect, 2020.
- Longitudinal Shifts of Solid Tumor and Liquid Biopsy Sequencing Concordance in Metastatic Breast Cancer. JCO Precision Oncology.
- Liquid biopsy in breast cancer: Redefining precision medicine. PMC, 2025.
- DNBSEQ sequencing platform comprehensively supports WGS, single-cell, and microbiology research with eye-catching Q40 data. MGI Tech.
